Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma

被引：2
|
作者：
Kamide, Yosuke [1 ]
Kaira, Kyoichi [1 ]
Watanabe, Takuya [1 ]
Kuribayashi, Shiko [1 ]
Ozawa, Atsushi [1 ]
Koga, Yasuhiko [1 ]
Ono, Akihiro [1 ]
Sunaga, Noriaki [1 ]
Hisada, Takeshi [1 ]
Oyama, Tetsunari [2 ]
Yamada, Masanobu [1 ]
机构：
[1] Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Maebashi, Gunma, Japan
[2] Gunma Univ, Grad Sch Med, Gunma Univ Hosp, Dept Diagnost Pathol, Maebashi, Gunma, Japan
来源：
INTERNAL MEDICINE | 2015年 / 54卷 / 22期
关键词：
pleomorphic carcinoma; ALK rearrangement; lung cancer; EPITHELIAL-MESENCHYMAL TRANSITION; SENSITIVITY; DETERMINANT; RESISTANCE;
D O I：
10.2169/internalmedicine.54.4987
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 55-year-old woman was diagnosed with a tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) rearrangement-positive lung adenocarcinoma and treated with chemotherapy consisting of crizotinib, a tyrosine kinase inhibitor of ALK, as second-line chemotherapy. However, the size of the metastatic adrenal lesion increased, and the patient died due to multiple organ failure. An autopsy report revealed that the metastatic lesion of the adrenal tumor was ALK rearrangement-positive pleomorphic carcinoma. The epithelial-mesenchymal transition (EMT) marker vimentin was immunohistochemically positive in both the lung and adrenal lesions. The present case report suggests the possibility of transformation into pleomorphic carcinoma as a result of EMT in patients with ALK rearrangement-positive lung cancer.
引用
收藏
页码：2905 / 2909
页数：5
相关论文
共 50 条
  • [1] Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
    Iwama, Eiji
    Okamoto, Isamu
    Harada, Taishi
    Takayama, Koichi
    Nakanishi, Yoichi
    [J]. ONCOTARGETS AND THERAPY, 2014, 7 : 375 - 385
  • [2] A Rare Case of Pleomorphic Carcinoma of the Lung Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement
    Shiroyama, Takayuki
    Tanaka, Ayako
    Tamiya, Motohiro
    Hamaguchi, Masanari
    Osa, Akio
    Takeoka, Sawa
    Tani, Eriko
    Azuma, Yuichiro
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Kimura, Kenji
    Kadota, Yoshihisa
    Kawahara, Kunimitsu
    Hirashima, Tomonori
    Kawase, Ichiro
    [J]. INTERNAL MEDICINE, 2015, 54 (21) : 2741 - 2743
  • [3] Metastatic Anaplastic Lymphoma Kinase Rearrangement-Positive Adenocarcinoma of Occult Primary Mimicking Ovarian Cancer
    Chahin, Michael
    Krishnan, Nithya
    Matthews-Hew, Trevanne
    Hew, Jason
    Pham, Dat
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (07)
  • [4] Hypertrophic Pulmonary Osteoarthropathy in Anaplastic Lymphoma Kinase (ALK)-positive Lung Cancer
    Komatsu, Masamichi
    Yasuo, Masanori
    Kobayashi, Nobumitsu
    Tateishi, Kazunari
    Ushiki, Atsuhito
    Urushihata, Kazuhisa
    Yamamoto, Hiroshi
    Hanaoka, Masayuki
    Matoba, Hisanori
    Honda, Takayuki
    Ichikawa, Kosuke
    [J]. INTERNAL MEDICINE, 2015, 54 (16) : 2045 - 2049
  • [5] Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement-positive lung adenocarcinoma: A case report
    Takakuwa, Osamu
    Oguri, Tetsuya
    Yokoyama, Midori
    Hijikata, Hisatoshi
    Uemura, Takehiro
    Ohkubo, Hirotsugu
    Maeno, Ken
    Niimi, Akio
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 121 - 123
  • [6] Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer
    Ou, Sai-Hong Ignatius
    Shirai, Keisuke
    [J]. LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES, 2016, 893 : 179 - 187
  • [7] Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib
    Takegawa, N.
    Hayashi, H.
    Iizuka, N.
    Takahama, T.
    Ueda, H.
    Tanaka, K.
    Takeda, M.
    Nakagawa, K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (05) : 953 - 955
  • [8] Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib
    Yamamoto, Yuzo
    Okamoto, Isamu
    Otsubo, Kohei
    Iwama, Eiji
    Hamada, Naoki
    Harada, Taishi
    Takayama, Koichi
    Nakanishi, Yoichi
    [J]. INVESTIGATIONAL NEW DRUGS, 2015, 33 (05) : 1148 - 1150
  • [9] Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
    Lin, Liping
    Huang, Fuxi
    Chen, Fang
    He, Yan
    Hu, Jiazhu
    Cao, Xiaolong
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (08) : 3491 - 3497
  • [10] Hepatoid Carcinoma of the Lung with Anaplastic Lymphoma Kinase Gene Rearrangement
    Khozin, Sean
    Roth, Mark J.
    Rajan, Arun
    Smith, Karen
    Thomas, Anish
    Berman, Arlene
    Giaccone, Giuseppe
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : E29 - E31
12345